Ketamine for Bipolar Depression

Yes — ketamine has shown rapid and significant antidepressant effects in bipolar depression in multiple clinical trials. A 2012 Yale study (Zarate et al.) found that a single ketamine infusion produced significant improvement in bipolar depression patients who were on a mood stabilizer. Response rates were 60-70% in the clinical trial setting.

This is an important safety consideration. Research suggests the risk is low — a 2017 meta-analysis found that ketamine did not increase the risk of affective switch (switching to mania or hypomania) in bipolar patients when used alongside a mood stabilizer. However, we monitor every bipolar patient closely for any signs of activation or elevated mood.

Ketamine is typically used as an add-on to your existing mood stabilizer, not a replacement. Most studies required participants to be on a stable dose of lithium, valproate, lamotrigine, or another mood stabilizer before starting ketamine. We'll coordinate with your existing prescriber.

Bipolar depression is more treatment-resistant, carries a higher risk of antidepressant-induced mood switching, and often requires a different approach from the start. Traditional antidepressants — particularly TCAs and some SSRIs — are generally avoided or used carefully in bipolar depression. Ketamine's non-monoamine mechanism makes it an attractive option for this population.

The protocol is similar to what we use for treatment-resistant unipolar depression: a 6-infusion induction series over 4 weeks, followed by maintenance infusions as needed. Your response is assessed after each treatment using validated mood scales.

No. Ketamine is FDA-approved as an anesthetic but used off-label for psychiatric conditions including bipolar depression. Spravato (esketamine) is FDA-approved for treatment-resistant depression (the unipolar form) but not specifically indicated for bipolar depression. IV ketamine for bipolar depression is considered investigational.